Computational modelling prediction and clinical validation of impact of benralizumab on airway smooth muscle mass in asthma
Asthma is a heterogeneous condition characterised by chronic inflammation and airway remodelling. T2-mediated airway inflammation, characterised by interleukin (IL)-4, IL-5 and IL-13, has been the recent focus of pharmacotherapy, with a host of targeted biologic agents now available to clinicians [1]. The anti-IL-5 receptor agent, benralizumab, causes depletion of eosinophils and basophils via antibody-dependent cell-mediated cytotoxicity in blood; however, the mechanism of action in the tissue is uncertain. Benralizumab has reduced exacerbations and improved lung function in clinical trials. Benralizumab leads to a reduction in ASM mass in asthmatic airways, which can be predicted using a computational model <http://bit.ly/2OwNMBy>